Vimarsana
Biggest News Aggregation in the World

Page 37 - Human Use News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Human Use. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Human Use Today - Breaking & Trending Today

Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update - Vimarsana News

Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update

Company to host a webcasttoday at 8:30 a.m. Eastern TimeNEW YORK, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the ...

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023 - Vimarsana News

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023

Results Reflect Continued Strength of In-Line and New Products, Pipeline Execution and Business Development Activity, Supporting Growth Momentum into 2024   Reports Fourth Quarter Revenues of...

Trimetazidine: What is the drug that Russian figure skater Kamila Valieva tested positive for? - Vimarsana News

Trimetazidine: What is the drug that Russian figure skater Kamila Valieva tested positive for?

What exactly is the drug that triggered a high-profile doping scandal and eventually led to Valieva's ban and disqualification?

Source: ksbw.com
Astellas Submits SNDA In Japan For PADCEV-KEYTRUDA For Advanced Bladder Cancer Treatment - Vimarsana News

Astellas Submits SNDA In Japan For PADCEV-KEYTRUDA For Advanced Bladder Cancer Treatment

(RTTNews) - Astellas Pharma Inc. (ALPMY, ALPMY) announced the submission of a Supplemental New Drug Application or sNDA to Japan's Ministry of Hea...

Astellas Pharma Inc. Submits Supplemental New Drug Application in Japan for PADCEV with KEYTRUDA for First-Line Treatment of Advanced Bladder Cancer - Vimarsana News

Astellas Pharma Inc. Submits Supplemental New Drug Application in Japan for PADCEV with KEYTRUDA for First-Line Treatment of Advanced Bladder Cancer

Astellas Pharma Inc. announced the submission of a Supplemental New Drug Application on January 31 to Japan's Ministry of Health, Labour and Welfare for PADCEV?? ) with KEYTRUDA®? as a combination...